What is Ribociclib (Dose #2) used for?

Ribociclib (Dose #2) is indicated for Hormone receptor positive malignant neoplasm of breast.

Who makes Ribociclib (Dose #2)?

Ribociclib (Dose #2) is developed by Pfizer Inc..

What development phase is Ribociclib (Dose #2) in?

Ribociclib (Dose #2) is FDA-approved (marketed).

What is the generic name of Ribociclib (Dose #2)?

ribociclib-dose-2 is the generic (nonproprietary) name of Ribociclib (Dose #2).

Last reviewed 2026-04-20 · How we verify

Ribociclib (Dose #2) (ribociclib-dose-2)

Pfizer Inc. · FDA-approved active Quality 21/100

At a glance

Generic name	ribociclib-dose-2
Sponsor	Pfizer Inc.
Target	Ferrochelatase, mitochondrial, Mitogen-activated protein kinase kinase kinase 1, Calcium/calmodulin-dependent protein kinase type II subunit delta
Phase	FDA-approved
Annual revenue	787

Approved indications

Hormone receptor positive malignant neoplasm of breast

Common side effects

No common side effects on file.

Key clinical trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ribociclib (Dose #2) CI brief — competitive landscape report
Ribociclib (Dose #2) updates RSS · CI watch RSS
Pfizer Inc. portfolio CI